Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) is anticipated to post its resultson Friday, April 24th. Analysts expect Astellas Pharma to post earnings of $0.1775 per share and revenue of $3.2836 billion for the quarter.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.15. Astellas Pharma had a return on equity of 23.62% and a net margin of 15.63%.The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.21 billion. On average, analysts expect Astellas Pharma to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Astellas Pharma Stock Down 1.6%
Shares of ALPMY opened at $16.19 on Friday. The company has a market capitalization of $29.30 billion, a price-to-earnings ratio of 13.61 and a beta of 0.17. The stock's 50-day moving average price is $15.87 and its 200-day moving average price is $13.69. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23. Astellas Pharma has a 52 week low of $8.97 and a 52 week high of $17.35.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. Smbc Nikko Sec. upgraded Astellas Pharma to a "hold" rating in a research report on Monday, February 16th. Jefferies Financial Group upgraded Astellas Pharma from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 24th. Finally, Citigroup downgraded Astellas Pharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold".
Check Out Our Latest Stock Analysis on Astellas Pharma
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.
Core products in Astellas' portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A forward-looking investment report spotlighting the seven space companies best positioned to benefit from accelerating commercialization in 2026. It explores key industry trends, major growth catalysts, and the stocks shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
